Summary

Myasthenia Gravis Treatment Trends and Forecast
The future of the global myasthenia gravis treatment market looks promising with opportunities in the hospital and clinic markets. The global myasthenia gravis treatment market is expected to reach an estimated $2.5 billion by 2030 with a CAGR of 6.3% from 2024 to 2030. The major drivers for this market are increasing awareness of rare diseases, the introduction of biologics and approval of promising medications, along with the growing use of immunotherapies.

A more than 150-page report is developed to help in your business decisions. Sample figures with some insights are shown below.

Myasthenia Gravis Treatment by Segment
The study includes a forecast for the global myasthenia gravis treatment by treatment type, end use, and region.

Myasthenia Gravis Treatment Market by Treatment Type [Shipment Analysis by Value from 2018 to 2030]:
• Cholinesterase Inhibitors
• Chronic Immunomodulators
• Monoclonal Antibodies
• Rapid Immunotherapies
• Thymectomy
• Others

Myasthenia Gravis Treatment Market by End Use [Shipment Analysis by Value from 2018 to 2030]:
• Hospitals
• Clinics
• Others

Myasthenia Gravis Treatment Market by Region [Shipment Analysis by Value from 2018 to 2030]:
• North America
• Europe
• Asia Pacific
• The Rest of the World

List of Myasthenia Gravis Treatment Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies myasthenia gravis treatment companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the myasthenia gravis treatment companies profiled in this report include-
• Alexion Pharmaceutical
• Grifols
• Avadel Pharmaceuticals
• Novartis
• Pfizer
• AbbVie
• F. Hoffmann-La Roche

Myasthenia Gravis Treatment Market Insights
Lucintel forecasts that monoclonal antibodies will remain the largest segment over the forecast period due to high degree of precision and improved efficacy in the treatment of myasthenia gravis.

North America will remain the largest region over the forecast period due to rise of immunotherapies and monoclonal antibodies, increased healthcare expenditure, the presence of approved R&D facilities as well as favorable reimbursement scenarios.

Features of the Global Myasthenia Gravis Treatment Market

Market Size Estimates: Myasthenia gravis treatment market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends (2018 to 2023) and forecast (2024 to 2030) by various segments and regions.
Segmentation Analysis: Myasthenia gravis treatment market size by treatment type, end use, and region in terms of value ($B).
Regional Analysis: Myasthenia gravis treatment market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
Growth Opportunities: Analysis of growth opportunities in different treatment type, end use, and regions for the myasthenia gravis treatment market.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the myasthenia gravis treatment market.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.

FAQ

Q1. What is the myasthenia gravis treatment market size?
Answer: The global myasthenia gravis treatment market is expected to reach an estimated $2.5 billion by 2030.

Q2. What is the growth forecast for myasthenia gravis treatment market?
Answer: The global myasthenia gravis treatment market is expected to grow with a CAGR of 6.3% from 2024 to 2030.

Q3. What are the major drivers influencing the growth of the myasthenia gravis treatment market?
Answer: The major drivers for this market are increasing awareness of rare diseases, the introduction of biologics and approval of promising medications, along with the growing use of immunotherapies.

Q4. What are the major segments for myasthenia gravis treatment market?
Answer: The future of the global myasthenia gravis treatment market looks promising with opportunities in the hospital and clinic markets.

Q5. Who are the key myasthenia gravis treatment market companies?
Answer: Some of the key myasthenia gravis treatment companies are as follows:
• Alexion Pharmaceutical
• Grifols
• Avadel Pharmaceuticals
• Novartis
• Pfizer
• AbbVie
• F. Hoffmann-La Roche






Q6. Which myasthenia gravis treatment market segment will be the largest in future?
Answer: Lucintel forecasts that monoclonal antibodies will remain the largest segment over the forecast period due to high degree of precision and improved efficacy in the treatment of myasthenia gravis.

Q7. In myasthenia gravis treatment market, which region is expected to be the largest in next 5 years?
Answer: North America will remain the largest region over the forecast period due to rise of immunotherapies and monoclonal antibodies, increased healthcare expenditure, the presence of approved R&D facilities as well as favorable reimbursement scenarios.

Q.8 Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.

This report answers following 11 key questions:

Q.1. What are some of the most promising, high-growth opportunities for the myasthenia gravis treatment market by treatment type (cholinesterase inhibitors, chronic immunomodulators, monoclonal antibodies, rapid immunotherapies, thymectomy, and others), end use (hospitals, clinics, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

ページTOPに戻る

Table of Contents

Table of Contents

1. Executive Summary

2. Global Myasthenia Gravis Treatment Market : Market Dynamics
2.1: Introduction, Background, and Classifications
2.2: Supply Chain
2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2018 to 2030
3.1. Macroeconomic Trends (2018-2023) and Forecast (2024-2030)
3.2. Global Myasthenia Gravis Treatment Market Trends (2018-2023) and Forecast (2024-2030)

3.3: Global Myasthenia Gravis Treatment Market by Treatment Type
3.3.1: Cholinesterase Inhibitors
3.3.2: Chronic Immunomodulators
3.3.3: Monoclonal Antibodies
3.3.4: Rapid Immunotherapies
3.3.5: Thymectomy
3.3.6: Others




3.4: Global Myasthenia Gravis Treatment Market by End Use
3.4.1: Hospitals
3.4.2: Clinics
3.4.3: Others




























4. Market Trends and Forecast Analysis by Region from 2018 to 2030
4.1: Global Myasthenia Gravis Treatment Market by Region
4.2: North American Myasthenia Gravis Treatment Market
4.2.1: North American Myasthenia Gravis Treatment Market by Treatment Type: Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, and Others
4.2.2: North American Myasthenia Gravis Treatment Market by End Use: Hospitals, Clinics, and Others



4.3: European Myasthenia Gravis Treatment Market
4.3.1: European Myasthenia Gravis Treatment Market by Treatment Type: Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, and Others
4.3.2: European Myasthenia Gravis Treatment Market by End Use: Hospitals, Clinics, and Others



4.4: APAC Myasthenia Gravis Treatment Market
4.4.1: APAC Myasthenia Gravis Treatment Market by Treatment Type: Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, and Others
4.4.2: APAC Myasthenia Gravis Treatment Market by End Use: Hospitals, Clinics, and Others



4.5: ROW Myasthenia Gravis Treatment Market
4.5.1: ROW Myasthenia Gravis Treatment Market by Treatment Type: Cholinesterase Inhibitors, Chronic Immunomodulators, Monoclonal Antibodies, Rapid Immunotherapies, Thymectomy, and Others
4.5.2: ROW Myasthenia Gravis Treatment Market by End Use: Hospitals, Clinics, and Others



5. Competitor Analysis
5.1: Product Portfolio Analysis
5.2: Operational Integration
5.3: Porter’s Five Forces Analysis

6. Growth Opportunities and Strategic Analysis
6.1: Growth Opportunity Analysis
6.1.1: Growth Opportunities for the Global Myasthenia Gravis Treatment Market by Treatment Type
6.1.2: Growth Opportunities for the Global Myasthenia Gravis Treatment Market by End Use
6.1.3: Growth Opportunities for the Global Myasthenia Gravis Treatment Market by Region

6.2: Emerging Trends in the Global Myasthenia Gravis Treatment Market

6.3: Strategic Analysis
6.3.1: New Product Development
6.3.2: Capacity Expansion of the Global Myasthenia Gravis Treatment Market
6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Myasthenia Gravis Treatment Market
6.3.4: Certification and Licensing

7. Company Profiles of Leading Players
7.1: Alexion Pharmaceutical
7.2: Grifols
7.3: Avadel Pharmaceuticals
7.4: Novartis
7.5: Pfizer
7.6: AbbVie
7.7: F. Hoffmann-La Roche